Logomix is a US/Japan-based company transforming cell therapy development through Geno-Writing™, a proprietary genome engineering engine. Purpose-built for complex ex vivo applications, our platform enables precise, megabase-scale modifications in human iPSCs to maximize therapeutic potential. We achieve unparalleled speed and accuracy, integrating 12+ transgenes within 2.5 months.

While advancing a proprietary Type 1 Diabetes (T1D) program, our primary objective at JPM is to explore broad strategic collaborations beyond T1D. We seek to empower biopharma partners by applying our large-scale engineering and CloneMax automated screening to diverse therapeutic areas—including oncology, immunology, and rare diseases. We offer a robust discovery engine to accelerate the design and manufacturing of next-generation, allogeneic iPSC-derived treatments across the healthcare spectrum.